An HIV-Free Generation Is Closer Than Ever—But Funding Cuts Threaten Progress
June 10, 2024
In 2015, the world set an ambitious goal: eliminate new HIV infections among children by 2030. By 2026, the target was tightened further—no baby should be born with HIV. Yet today, nearly 120,000 children are still infected annually, primarily through mother-to-child transmission during pregnancy, childbirth, or breastfeeding. The progress made over the past three decades has been nothing short of miraculous, but the gains are now at risk due to funding instability, shifting global health priorities, and persistent gaps in rural healthcare access.
The science to end pediatric HIV exists. The question is whether the world can deliver it equitably. Botswana proved it’s possible: the country eliminated mother-to-child transmission as a public health threat in 2023, a feat certified by the World Health Organization. But for most of sub-Saharan Africa—where 90% of new childhood HIV cases occur—the path remains fraught with obstacles.
At the heart of the challenge lies a stark reality: one child is infected with HIV every four and a half minutes, according to UNAIDS. While global antiretroviral therapy (ART) coverage for pregnant women living with HIV has surged from 10% in 2004 to 86% in 2022, critical gaps persist. About one in six pregnant women with HIV still lacks treatment, and half of those on treatment don’t adhere consistently—leading to 328 new infections daily, per UNAIDS’ 2023 Global AIDS Monitoring Report. The result? Roughly 75,000 children under five die annually from AIDS-related causes, a figure likely underreported due to diagnostic delays in remote regions.
The Science That Changed Everything
The turning point came in 1994, when U.S. Researchers discovered that HIV-positive pregnant women on antiretroviral therapy (ART) had less than a 1% chance of transmitting the virus to their babies. The findings were so compelling that the trial was halted early to offer treatment to the placebo group. By 1999, nearly 80% of HIV-positive pregnant women in the U.S. Were on ART, reducing transmission rates to 1.2% by 2003.
Yet for much of Africa, these breakthroughs arrived decades later. In 1999, Ugandan pediatric infectious disease specialist Dr. Philippa Musoke led a landmark study showing that two doses of Nevirapine—costing just $2 per dose at the time—cut mother-to-child transmission by 50%. Her work paved the way for global rollouts of WHO’s Option B+ strategy, which recommends lifelong ART for all HIV-positive pregnant women, regardless of CD4 count.
Botswana became the poster child for success. In 1999, it launched the world’s first free HIV treatment program for pregnant women, slashing transmission rates from 25% to under 1.2% within a decade. By 2023, the WHO certified Botswana as the first high-burden country to eliminate mother-to-child transmission as a public health threat—a milestone defined as less than 50 new infections per 100,000 live births annually.
Other nations followed, albeit with less dramatic results. Kenya’s coverage of HIV-positive pregnant women on ART jumped from virtually 0% in 2003 to 76% in 2008, reducing new childhood infections by 75% in five years. Yet today, Nigeria accounts for one in seven global pediatric HIV cases, with half of births occurring at home without skilled attendance, per Nigeria Health Watch. The disconnect? Free ART has been available for nearly two decades—but only 50% of eligible pregnant women access it.
Why Botswana Succeeded Where Others Struggled
The difference between Botswana and most of Africa boils down to three factors: resources, systems, and political will. Botswana’s diamond wealth—ranking among Africa’s richest nations per capita—funds 70% of its own HIV response, including testing, treatment, and peer mentorship programs. Other high-burden countries, like Nigeria and South Africa, rely heavily on PEPFAR (President’s Emergency Plan for AIDS Relief), which accounts for 90% of their HIV programming.
PEPFAR, launched in 2003, has been instrumental in preventing 7.8 million HIV infections in children since its inception, per official U.S. Government data. But the program’s future is uncertain. Under the Trump administration, PEPFAR shifted from global partnerships with NGOs to bilateral agreements requiring recipient countries to co-fund programs. While treatment funding remains stable, prevention and outreach budgets—critical for mother-to-child transmission—have been slashed.
A 2023 UNAIDS projection warns that sustained aid cuts could lead to 1.1 million additional childhood HIV infections by 2040 and 820,000 more deaths. The risk isn’t theoretical: In Lesotho, Mothers2Mothers, a peer-mentorship program that trains HIV-positive women to support others, lost 90% of its funding in 2023. Mentor mothers in some districts dropped from six to two, leaving 450,000 people without outreach services.
The Last Mile: Why Some Mothers Still Fall Through the Cracks
Even with ART widely available, 34% of children living with HIV remain undiagnosed, per WHO. The barriers are systemic:
- Lack of awareness: As recently as 2016, only 56% of young women in Uganda understood vertical transmission risks, per AVERT.
- Rural access: In Nigeria, half of births occur at home, often without skilled health workers to administer ART or test for HIV.
- Stigma: HIV-positive women in some communities face rejection when seeking prenatal care, forcing them to deliver in isolation.
- Supply chain failures: Stockouts of ART or rapid HIV tests—reported in 12 African countries in 2023, per MSF—leave mothers vulnerable.
The solution? Peer mentors like Liako Serobanyane, an HIV-positive woman in Lesotho who trains other mothers through Mothers2Mothers. “We know what it’s like to be rejected,” she says. “We know the fear of not knowing if your baby will live. That’s why we have to go to them—not wait for them to come to the clinic.”
Serobanyane’s work is a microcosm of the “last mile” problem: reaching the 15% of pregnant women with HIV who still don’t know their status and the 50% who don’t adhere to treatment. Without sustained funding for community health workers, the progress of the past 20 years could unravel.
What Happens Next? The Road to 2030
The excellent news? New tools are on the horizon. Lenacapavir, an injectable HIV prevention drug approved by the FDA in 2022, could reduce transmission by 97% when taken monthly. Clinical trials in sub-Saharan Africa are underway, but rollout depends on funding and supply chain infrastructure.
The bad news? The window to act is closing. By 2026, the world must:
- Scale peer mentorship programs like Mothers2Mothers, which studies show increase ART adherence by 40%, per The Lancet HIV.
- Strengthen rural health systems to ensure 95% of births occur in facilities with HIV testing and ART, as recommended by WHO’s 2021 guidelines.
- Secure predictable funding for prevention programs, not just treatment. The Global Fund to Fight AIDS, Tuberculosis and Malaria estimates a $14 billion annual shortfall by 2025 to meet 2030 targets.
- Address legal barriers, such as 28 African countries where HIV criminalization laws deter testing and treatment, per AVERT.
The next critical checkpoint is the 2024 UN High-Level Meeting on AIDS, where world leaders will review progress toward the 2030 Sustainable Development Goals. Advocates warn that without urgent action, the HIV-free generation could slip further out of reach.
A Call to Action
The story of pediatric HIV is one of humanity’s greatest public health triumphs—and its most fragile. Botswana proved elimination is possible. The question now is whether the world can replicate that success at scale. With $14 billion needed annually to close the funding gap and millions of mothers still missing critical care, the stakes couldn’t be higher.
What’s needed isn’t just money, but political will. As Doris Macharia, president of the Elizabeth Glaser Pediatric AIDS Foundation, puts it: “Every child born with HIV is unacceptable. Every mother who acquires HIV during pregnancy is unacceptable. These are not statistics—they are lives You can save.”
For readers who want to help:
- Donate to UNAIDS’ global fund or the Global Fund.
- Advocate for PEPFAR’s continued support through your representatives.
- Share verified resources, like AVERT’s guide to preventing mother-to-child transmission.
Share this story to keep the pressure on. The clock is ticking—and the next generation’s health depends on it.
–>
–>